Literature DB >> 12213338

The assessment of antigen-specific CD8+ T cells through the combination of MHC class I tetramer and intracellular staining.

Victor Appay1, Sarah L Rowland-Jones.   

Abstract

Peptide-bound histocompatibility leukocyte antigen (HLA) class I tetramers enable a precise identification of antigen-specific CD8+ T cells using flow cytometry. The combination of this technology with intracellular staining techniques opens up significantly better ways of studying these cells than previously possible, allowing immunologists to look at their life cycle (activation and proliferation), manner of death (aging and apoptosis) and effector function (cytotoxic potential and cytokine production). In this review, we hope to provide an overview of these possibilities, as well as making specific suggestions about the use of intracellular staining techniques in the study of antigen-specific T cells. Understanding how antigen-specific cells develop and function in different circumstances and pathologies will be the key to unravelling the secrets of our cellular immune system.

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 12213338     DOI: 10.1016/s0022-1759(02)00195-3

Source DB:  PubMed          Journal:  J Immunol Methods        ISSN: 0022-1759            Impact factor:   2.303


  26 in total

1.  Analyzing cellular immunity to AAV in a canine model using ELISPOT assay.

Authors:  Zejing Wang; Rainer Storb; Stephen J Tapscott; Stanley Riddell
Journal:  Methods Mol Biol       Date:  2012

2.  Enhanced responsiveness to antigen contributes more to immunological memory in CD4 T cells than increases in the number of cells.

Authors:  John T Bates; R Pat Bucy
Journal:  Immunology       Date:  2005-11       Impact factor: 7.397

3.  T cell costimulatory molecules in anti-viral immunity: Potential role in immunotherapeutic vaccines.

Authors:  Tania H Watts; Edward M Bertram; Jacob Bukczynski; Tao Wen
Journal:  Can J Infect Dis       Date:  2003-07

4.  Soluble MHC-peptide complexes: tools for the monitoring of T cell responses in clinical trials and basic research.

Authors:  Philippe Guillaume; Danijel Dojcinovic; Immanuel F Luescher
Journal:  Cancer Immun       Date:  2009-09-25

5.  Evidence of premature immune aging in patients thymectomized during early childhood.

Authors:  Delphine Sauce; Martin Larsen; Solène Fastenackels; Anne Duperrier; Michael Keller; Beatrix Grubeck-Loebenstein; Christophe Ferrand; Patrice Debré; Daniel Sidi; Victor Appay
Journal:  J Clin Invest       Date:  2009-09-21       Impact factor: 14.808

6.  Viral suppression and immune restoration in the gastrointestinal mucosa of human immunodeficiency virus type 1-infected patients initiating therapy during primary or chronic infection.

Authors:  Moraima Guadalupe; Sumathi Sankaran; Michael D George; Elizabeth Reay; David Verhoeven; Barbara L Shacklett; Jason Flamm; Jacob Wegelin; Thomas Prindiville; Satya Dandekar
Journal:  J Virol       Date:  2006-08       Impact factor: 5.103

7.  Novel toll-like receptor 2 ligands for targeted pancreatic cancer imaging and immunotherapy.

Authors:  Amanda Shanks Huynh; Woo Jin Chung; Hyun-Il Cho; Valerie E Moberg; Esteban Celis; David L Morse; Josef Vagner
Journal:  J Med Chem       Date:  2012-11-08       Impact factor: 7.446

8.  Upregulation of interleukin 7 receptor alpha and programmed death 1 marks an epitope-specific CD8+ T-cell response that disappears following primary Epstein-Barr virus infection.

Authors:  Delphine Sauce; Martin Larsen; Rachel J M Abbott; Andrew D Hislop; Alison M Leese; Naeem Khan; Laura Papagno; Gordon J Freeman; Alan B Rickinson
Journal:  J Virol       Date:  2009-07-15       Impact factor: 5.103

9.  Granzyme B production distinguishes recently activated CD8(+) memory cells from resting memory cells.

Authors:  Tobias M Nowacki; Stefanie Kuerten; Wenji Zhang; Carey L Shive; Christian R Kreher; Bernhard O Boehm; Paul V Lehmann; Magdalena Tary-Lehmann
Journal:  Cell Immunol       Date:  2007-09-07       Impact factor: 4.868

10.  Preferential amplification of CD8 effector-T cells after transcutaneous application of an inactivated influenza vaccine: a randomized phase I trial.

Authors:  Behazine Combadière; Annika Vogt; Brice Mahé; Dominique Costagliola; Sabrina Hadam; Olivia Bonduelle; Wolfram Sterry; Shlomo Staszewski; Hans Schaefer; Sylvie van der Werf; Christine Katlama; Brigitte Autran; Ulrike Blume-Peytavi
Journal:  PLoS One       Date:  2010-05-26       Impact factor: 3.240

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.